Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IgA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    681 result(s) found for: IgA. Displaying page 4 of 35.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000443-99 Sponsor Protocol Number: MIGAN Start Date*: 2008-04-09
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study fo...
    Medical condition: progressive IgA-Nephritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029143 Nephritis-glomerular LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001545-81 Sponsor Protocol Number: 112269 Start Date*: 2015-06-10
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IV, double-blind, randomised, placebo-controlled study to evaluate immunogenicity, reactogenicity and safety of GlaxoS-mithKline (GSK) Biologicals’ oral live attenuated HRV vaccine in healt...
    Medical condition: Rotavirus gateroenteritis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000900-40 Sponsor Protocol Number: LP0133-1273 Start Date*: 2019-01-15
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice daily topical application of delgocitinib cream 1, 3, 8, and 20 mg/g...
    Medical condition: Chronic hand eczema
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10066695 Chronic hand dermatitis LLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2023-000461-13 Sponsor Protocol Number: 171-7151-201 Start Date*: 2023-04-19
    Sponsor Name:Intrepid Therapeutics Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Once or Twice-...
    Medical condition: Facial Acne Vulgaris
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-004164-60 Sponsor Protocol Number: CUV040 Start Date*: 2022-05-19
    Sponsor Name:CLINUVEL (UK) LTD
    Full Title: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease.
    Medical condition: Variegate Porphyria (VP)-related skin disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000972-38 Sponsor Protocol Number: 212692 Start Date*: 2023-05-17
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase III, observer-blind, randomized, multicenter study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Rotarix Porcine circovirus (PCV)-free liquid a...
    Medical condition: Healthy volunteers (active immunization of infants against gastroenteritis due to rotavirus infection)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000940-26 Sponsor Protocol Number: CASM981C2314 Start Date*: 2004-09-24
    Sponsor Name:Novartis Pharma
    Full Title: A 22-week randomized, multicenter, parallel-group, double-blind study to compare a pimecrolimus 1 % (Elidel) twice daily (b.i.d.) maintenance dosing regimen to a once daily (o.d.) maintenance dosin...
    Medical condition: Atopic dermatitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000489-40 Sponsor Protocol Number: IZD174-002 Start Date*: 2020-09-22
    Sponsor Name:Inflazome (Australia) Pty Ltd.
    Full Title: A Multi-Centre, Randomised, Open-Label, Phase IIb Study to Evaluate the Safety, Tolerability and Efficacy of IZD174 in Patients with Cryopyrin Associated Periodic Syndromes
    Medical condition: Cryopyrin-associated periodic syndrome (CAPS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068850 Cryopyrin associated periodic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000595-15 Sponsor Protocol Number: CZPL389A2203E1 Start Date*: 2019-03-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double blind, multicenter extension to CZPL389A2203 dose-ranging study to assess the short-term and long-term safety and efficacy of oral ZPL389 with concomitant or intermittent use o...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) DE (Temporarily Halted) IS (Completed) NL (Temporarily Halted) SK (Prematurely Ended) BE (Prematurely Ended) EE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003425-42 Sponsor Protocol Number: PS0009 Start Date*: 2018-03-16
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate ...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) BE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000215-92 Sponsor Protocol Number: BYH1003 Start Date*: 2019-07-02
    Sponsor Name:Bay Pharma GmbH
    Full Title: Prospective, randomized, double blinded, placebo controlled, multicentre study for the evaluation of efficacy and safety of a Tacrolimus-containing solution (TACRO-Skin) in subjects with mild to se...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037157 Psoriasis of scalp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004184-79 Sponsor Protocol Number: NIAD-01 Start Date*: 2013-05-01
    Sponsor Name:Dermal Laboratories Limited
    Full Title: A placebo controlled evaluation of a developmental gel for the treatment of atopic eczema
    Medical condition: The medical condition to be investigated in this study is atopic eczema, also known as atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003641 Atopic eczema LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007525-39 Sponsor Protocol Number: CAIN457A2211 Start Date*: 2009-08-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with...
    Medical condition: Moderate to severe plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IS (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004899-30 Sponsor Protocol Number: 111187 Start Date*: 2016-12-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Multi-center, Randomised, Double-blind, Parallel, Placebo Controlled Study Of 0.05% Clobetasone Butyrate Cream in Subjects with Eczema to evaluate the Efficacy and Safety.
    Medical condition: Eczema
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000375-13 Sponsor Protocol Number: LIS-144 Start Date*: 2011-05-02
    Sponsor Name:National Institute of Public Health and Environment (RIVM, the Netherlands)
    Full Title: Study to determine the appropriate age for a second immunization with the Meningococcal C conjugated vaccine.
    Medical condition: The vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup C.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001049-38 Sponsor Protocol Number: CLNP023A2301 Start Date*: 2020-12-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients
    Medical condition: IgA Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) NO (Completed) FI (Completed) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) SI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002022-37 Sponsor Protocol Number: CNTO1959PSO3006 Start Date*: 2016-09-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects ...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002898-37 Sponsor Protocol Number: CAIN457A2326 Start Date*: 2016-05-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) IS (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-005609-28 Sponsor Protocol Number: RAV-IgA Start Date*: 2022-03-18
    Sponsor Name:Dr. Alfons Segarra Medrano
    Full Title: A PILOT PROOF-OF–CONCEPT STUDY TO ASSESS THE EFFICACY AND SAFETY OF A 6 MONTHS RAVULIZUMAB TREATMENT IN PATIENTS WITH FLARES OF CORTICOSTEROID-RESISTANT IDIOPATHIC IgA NEPHROPATHY
    Medical condition: Treatment for IgA nephropathy flares
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002332-16 Sponsor Protocol Number: RC31-16-8917 Start Date*: 2017-10-03
    Sponsor Name:Toulouse Hospital
    Full Title: Evaluation of the efficacy of injections of botulinic toxin in plantar lesions of patients suffering from localized epidermolysis bullosa simplex : double blind randomized controlled study.
    Medical condition: localized epidermolysis bullosa simplex
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 11:59:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA